Ergocalciferol and Specific gravity urine decreased - a phase IV clinical study of FDA data

Summary:

Specific gravity urine decreased is reported as a side effect among people who take Ergocalciferol (ergocalciferol), especially for people who are female, 30-39 old, also take Benadryl, and have Relapsing-remitting multiple sclerosis.

The phase IV clinical study analyzes which people have Specific gravity urine decreased when taking Ergocalciferol. It is created by eHealthMe based on reports of 32,546 people who have side effects when taking Ergocalciferol from the FDA, and is updated regularly.

What is Ergocalciferol?

Ergocalciferol has active ingredients of ergocalciferol. It is often used in rickets. eHealthMe is studying from 32,652 Ergocalciferol users. Check the latest studies of Ergocalciferol.

What is Specific gravity urine decreased?

Specific gravity urine decreased is found to be associated with 66 drugs and 78 conditions by eHealthMe. Check the latest studies of Specific gravity urine decreased.

On Jul, 17, 2026

32,546 people reported to have side effects when taking Ergocalciferol.
Among them, 18 people (0.06%) have Specific gravity urine decreased.

Could Ergocalciferol cause Specific gravity urine decreased?

Among these 18 people:

What is the gender of people who have Specific gravity urine decreased when taking Ergocalciferol? *

female: 100 %
male: 0.0 %

What is the age of people who have Specific gravity urine decreased when taking Ergocalciferol? *

What are other drugs people take besides Ergocalciferol? *

What are other side effects people have besides Specific gravity urine decreased? *

Lymphocyte Count Decreased: 17 people, 94.44%
Rashes (redness): 17 people, 94.44%
Fatigue (feeling of tiredness): 15 people, 83.33%
Chest Pain: 13 people, 72.22%
Limb Discomfort (discomfort in leg): 12 people, 66.67%
Insomnia (sleeplessness): 12 people, 66.67%
Headache (pain in head): 11 people, 61.11%
Urine Abnormality: 11 people, 61.11%
Feeling Abnormal: 9 people, 50.00%
Oropharyngeal Pain: 9 people, 50.00%

What are the existing conditions these people have? *

Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 17 people, 94.44%
Constipation: 9 people, 50.00%
Polycystic Ovary Disease (cysts in the ovaries that occurs when the follicle stops developing): 6 people, 33.33%
Neuralgia (pain in one or more nerves): 6 people, 33.33%
Irritable Bowel Syndrome: 6 people, 33.33%
Chest Pain: 5 people, 27.78%
Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 4 people, 22.22%
Birth Control: 3 people, 16.67%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 11.11%
Headache (pain in head): 2 people, 11.11%

* Approximation only. Some reports may have incomplete information.

Do you take Ergocalciferol and have Specific gravity urine decreased?

- Check whether Specific gravity urine decreased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ergocalciferol:

Ergocalciferol (32,652 reports)

Browse all side effects of Ergocalciferol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Specific gravity urine decreased:

Specific gravity urine decreased (66 drugs)

Browse all the conditions that are associated with Specific gravity urine decreased:

Specific gravity urine decreased (78 conditions)

Related publications that referenced our studies

Kapoor S, "Influence of Vitamin D Consumption and Levels on the Development of Psychiatric Disorders", Lee, Y. J., & Park, K. (2018). Secondary Raynaud’s Phenomenon and Skin Necrosis of Toes in the Paraplegic Patient with Hypertension.?Drug safety-case reports,?5(1), 7., 2014 Aug .
Kapoor S, "Influence of Vitamin D Consumption and Levels on the Development of Psychiatric Disorders", Lee, Y. J., & Park, K. (2018). Secondary Raynaud’s Phenomenon and Skin Necrosis of Toes in the Paraplegic Patient with Hypertension.?Drug safety-case reports,?5(1), 7., 2014 Aug .

How the study uses the data?

The study uses data from the FDA. It is based on ergocalciferol (the active ingredients of Ergocalciferol) and Ergocalciferol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.